Pancreatic Cancer Drugs Market to Reach $3.5 Billion by 2035

Pancreatic cancer drugs market was valued at $1.8 billion in 2025 and is projected to reach $3.5 billion by 2035, registering a CAGR of 7.0% from 2026 to 2035. The market is driven by the rising global burden of pancreatic cancer, which remains one of the most lethal malignancies with increasing incidence rates. According to PubMed Central, epidemiological research, the global incidence rate reached 6.22 per 100,000 population, with mortality at 5.74 per 100,000, reflecting the disease’s high fatality rate. Additionally, pancreatic cancer is recognized as a leading cause of cancer-related deaths worldwide, largely due to late-stage diagnosis and limited early detection. Aging populations, along with lifestyle factors such as smoking, obesity, and diabetes, are key contributors to the increasing disease prevalence. These factors are significantly driving demand for advanced chemotherapy, targeted therapy, and immunotherapy treatments across global healthcare systems.

Browse the full report description of “Pancreatic Cancer Drugs Market Size, Share & Trends Analysis Report By Cancer Type (Exocrine, and Neuroendocrine Tumors (PNETs)), By Therapy (Chemotherapy, Targeted Therapy, Immunotherapy), By Route of Administration (Intravenous (IV), Oral), and Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/pancreatic-cancer-drugs-market

Innovation Leaders Transforming the Pancreatic Cancer Drugs Market

The key players in the pancreatic cancer drugs market include Roche, Merck & Co., Pfizer, Novartis, and Bayer, among others. These companies are accelerating innovation through targeted therapies, immuno-oncology advancements, and combination treatment strategies. Their focus is on improving survival outcomes, enabling precision medicine driven by biomarkers, and expanding treatment options for aggressive tumour types. Increasing investments in oncology pipelines and strategic collaborations are further strengthening global drug development and commercialization efforts.

• In February 2026, for Cabometyx (cabozantinib) for the treatment of previously treated advanced neuroendocrine tumors, including pancreatic neuroendocrine tumors. The approval was based on positive Phase 3 CABINET trial results demonstrating improved clinical outcomes. This milestone strengthens Ipsen’s position in targeted therapies within the pancreatic cancer drugs market.

• In March 2025, Exelixis announced results from subgroup analysis of its Phase 3 CABINET trial evaluating cabozantinib, indicating improved progression-free survival in neuroendocrine tumor patients. The study included patients with advanced pancreatic neuroendocrine tumors (pNETs), supporting its clinical relevance in pancreatic cancer treatment. Additionally, the therapy received regulatory approvals for treating advanced pNETs, strengthening its position in the pancreatic cancer drugs market.

Market Coverage

• The market number available for – 2025–2035
• Base year- 2025
• Forecast period- 2026–2035
• Segment Covered-
• By Cancer Type
• By Therapy
• By Route of Administration
• Regions Covered-
• North America
• Europe
• Asia-Pacific
• Rest of the World
• Competitive Landscape: Roche, Merck & Co., Pfizer, Novartis, and Bayer, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Pancreatic Cancer Drugs Market Report Segment

By Cancer Type

• Exocrine Pancreatic Cancer
• Pancreatic Neuroendocrine Tumors (PNETs)

By Therapy

• Chemotherapy
• Targeted Therapy
• Immunotherapy

By Route of Administration

• Intravenous (IV)
• Oral

Global Pancreatic Cancer Drugs Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/pancreatic-cancer-drugs-market